Clearwater Analytics (CWAN) insider plans Rule 144 sale after recent stock disposals

Rhea-AI Filing Summary

Clearwater Analytics Holdings Inc. insider plans additional share sale under Rule 144. A holder has filed to sell 10,000 shares of common stock of CWAN through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 217,100.00. The issuer reports 288,154,032 common shares outstanding. The shares to be sold were acquired as restricted stock units from the issuer on 02/28/2024.

Over the past three months, the same account has sold 20,000 common shares on 11/12/2025 for gross proceeds of 404,194.00 and 5,327 common shares on 09/30/2025 for gross proceeds of 94,166.44. The filer represents that they are not aware of undisclosed material adverse information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10000	217100.00	288154032	12/08/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2024	Restricted Stock Units	Issuer			10000	02/28/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SOUVIK DAS 777 W. Main Street, Suite 900 Boise ID 83702	Common	11/12/2025	20000	404194.00
SOUVIK DAS 777 W. Main Street, Suite 900 Boise ID 83702	Common	09/30/2025	5327	94166.44

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Clearwater Analytics (CWAN) disclose?

The filing discloses that an insider-related account intends to sell 10,000 shares of Clearwater Analytics common stock under Rule 144, with an indicated aggregate market value of 217,100.00, through Morgan Stanley Smith Barney LLC on the NYSE.

How many Clearwater Analytics (CWAN) shares are being registered for potential sale in this Form 144?

The notice covers the potential sale of 10,000 shares of Clearwater Analytics common stock, tied to restricted stock units acquired from the issuer on 02/28/2024.

What recent CWAN stock sales by the same account are reported in the Form 144?

The document lists sales over the prior three months: 20,000 common shares sold on 11/12/2025 for gross proceeds of 404,194.00, and 5,327 common shares sold on 09/30/2025 for gross proceeds of 94,166.44.

How many Clearwater Analytics (CWAN) shares are outstanding according to this filing?

The securities information section reports that Clearwater Analytics has 288,154,032 common shares outstanding at the time referenced in the notice.

What is the source of the CWAN shares being sold under this Form 144?

The 10,000 shares covered by the notice come from restricted stock units acquired from the issuer on 02/28/2024, with the payment and acquisition dates both listed as that day.

Does the Form 144 for Clearwater Analytics (CWAN) mention Rule 10b5-1 trading plans?

The filing includes a section for the Date of Plan Adoption or Giving of Instruction, if relying on Rule 10b5-1, and states that by signing, the person represents they are not aware of undisclosed material adverse information as of the plan adoption or instruction date.